Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- FOSL +75.4%, NSPR +24.7%, CRTO +19.7%, TLND +16.5%, ACTG +15.3%, ACCO +11.2%,WIX +10.6%, CCS +10.1%, CARB +7.8%, (also announces agreement to acquire Mozy Inc from subsidiary of Dell Technologies for $145.8 mln in cash), ORBK +7.1%, TWLO +7%,BIDU +6.6%, SODA +6.5%, FLIR +5.8%, LPTH +4.8%, SINO +4.6%, GEO +3.7%, TEX +3.6%,WU +3.6%, DENN +3.5%, FANG +3.5%, (also initiates annual cash dividend of $0.50 per common share to be payable quarterly beginning with Q1 2018), ICL +3.5%, HLT +3.1%,HUBS +2.9%, IOSP +2.9%, MZOR +2.9%, CS +2.8%, TAP +2.7%, OMI +2.2%, MET +1.4%,IVTY +1.3%, BXMT +1.1%, LSCC +1%, .
M&A news:
- GCO +1.9% (Genesco to explore the sale of its Lids Sports Group business)
Other news:
- DBVT +34.9% (provides Viaskin Peanut progress update)
- ZSAN +33.9% (modestly rebounding)
- IPCC +21.8% (Infinity Property & Casualty being acquired by Kemper (KMPR) for $1.4 bln in cash and stock; both companies reported earnings)
- TRXC +12% (provides corporate update, files FDA 510(k) submission to expand the indication for use of its Senhance Surgical System)
- CMG +11.8% (confirms appointing Brian Niccol as CEO, effective March 5)
- TNDM +11.1% (closing of its previously announced underwritten public offering - several insiders including President disclosed the purchase of shares from the offering),RIOT +6% (files to withdraw Registration Statement on Form S-3 initially filed on April 20, 2017)
- AKAO +4.7% (following TTPH following Phase 3 trial failed to meet the co-primary efficacy endpoints)
- GNMX +3.5% (Adage increase passive stake to 9.91% from 3.5%, Baker Bros slightly decreases passive stake)
- NFLX +2.6% (Ryan Murphy and his Ryan Murphy Productions have entered into a multi-year deal to produce new series and films exclusively at Netflix, starting July 1, 2018)
- EXEL +2.4% (announces results from Phase 2 investigator-sponsored trial of Cabozantinib in the First-Line treatment of Metastatic Radioiodine-Refractory differentiated Thyroid Carcinoma )
- CELG +2.3% (authorizes the repurchase of an additional $5 billion of the Company's common stock)
- BKI +2.2% (announces 5 mln share secondary offering of common stock by selling shareholders and repurchase of 2 mln shares of common stock
- PSX +1.7% (Phillips 66 agreed to repurchase 35 mln shares from Berkshire subsidiary for $93.725 per share - Buffett says transaction was solely motivated by desire to eliminate regulatory requirements for 10%+ ownership)
- YY +1.4% (following BIDU results)
- VRX +1.4% (Valeant Pharma's Ortho Dermatologics division announced that the FDA accepted the NDA for JEMDEL1 (halobetasol propionate 0.01%) (IDP-122) lotion with a PDUFA action date of Oct. 5, 2018)
- SQ +1.2% (seeing continued strength boosted by Twitter (TWTR) CEO Jack Dorsey affirming slightly increased passive stake)
- AFL +1.1% (declared a two-for-one stock split of the company's common stock in the form of a 100% stock dividend payable)
Analyst comments:
- PTEN +5.4% (upgraded to Outperform from Market Perform at BMO Capital Markets),WU +3.3% (upgraded to Neutral from Underperform at Mizuho), ZLAB +2.7% (upgraded to Overweight from Neutral at JP Morgan), CRL +1.9% (upgraded to Buy from Hold at SunTrust), SINA +1.9% (upgraded to Buy from Outperform at CLSA), SGEN +1.8% (upgraded to Overweight from Neutral at JP Morgan), VIPS +1.8% (upgraded to Buy from Hold at HSBC Securities), VIAB +1.2% (upgraded to Neutral from Underweight at Atlantic Equities), IIVI +1.2% (initiated with a Overweight at Piper Jaffray), GBT +1.1% (initiated with a Buy at Janney), EMR +1% (upgraded to Outperform from Sector Perform at RBC Capital Mkts), FDC +1% (upgraded to Outperform from Neutral at Robert W. Baird), TGT +0.9% (upgraded to Outperform from Neutral at Robert W. Baird)